Eighty-two unselected cases of therapy-related myelodysplasia (t-MDS) or acute myeloid leukemia (t-AML
Introduction
Most of the recurrent and common cytogenetic and genetic abnormalities of t-MDS and t-AML have been related to specific types of primary therapy and can be classified in specific pathways. 1 Thus, the unbalanced chromosome aberrations with deletions or loss of 5q, of 7q or loss of whole chromosomes 5 or 7, 1-3 the deletions or loss of 17p including chromosome band 17p13 with mutations of p53, 4, 5 the formation of dicentric chromosomes 6 and the duplication or amplification of the unrearranged MLL gene, 7, 8 have all been significantly associated with primary therapy with alkylating agents. Other abnormalities such as the balanced translocations or inversions involving chromosome bands 11q23, 21q22, 16q22 and 17q12 with chimeric rearrangements of the MLL, the AML1, the CBFB and the RARA genes with various partner genes have all been significantly associated with primary therapy with topoisomerase II inhibitors. [9] [10] [11] [12] A normal karyotype is less common in t-MDS or t-AML as only observed in 10% of the cases and has not been associated with any specific type of therapy. 1, 2 In our systematic search for additional genetic abnormalities 
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Patients, materials and methods
Fifty-six unselected cases with t-MDS and 26 unselected cases of overt t-AML were studied at presentation of their leukemic complication. Clinical and cytogenetic data for the first 77 of these patients have been published previously and were recently summarized in a study of p53 mutations. 5 Total DNA and RNA was extracted, and cDNA synthesis was performed as previously described. 5 Analysis for internal tandem duplication of exons 11 and 12 of FLT3 was performed by genomic PCR as originally described 13 using the two primer pairs 11F/11R and 11F/12R. Abnormally migrating bands were cut out of the gel, re-amplified and subsequently sequenced.
Analysis for partial tandem duplication of the MLL gene was performed as originally reported 19 using primer sets 1 and 2. Positive results were verified by Southern analysis using the B859 probe 20 (kindly provided by Dr SA Schichman) according to standard procedures. Expand PCR (Boehringer Mannheim, Kvistgaard, Denmark) was applied for characterization of the intronic fusion point in cases with tandem duplication of MLL. The intron 6/2 and intron 8/2 fusion points were amplified using the forward/reverse primer pairs: 5Ј-gtccagagcagagcaaacag-3Ј(exon 6)/5Ј-agagtcaggtgctaactg-3Ј (intron1) and 5Ј-cccagggtggtttgctttctc-3Ј (exon 8)/5Ј-agagt caggtgctaactg-3Ј/(intron1).
Analysis for mutations in exons 1 to 10 of WT1 was performed by single stranded conformational polymorphism (SSCP) as previously described, 5 using primers as reported. 25 Only primer pair E1-3 was used for analysis of exon 1.
RT-PCR products for MLL and PCR products for FLT3 and WT1 were purified and sequenced in both directions with the aforementioned primers as previously described. 5 Expand PCR products were sequenced with the following primers: MLLint6-1F (5Ј-caagtttaggcttttagctgg-3Ј), MLLint8-2F (5Ј-ccacctttacaatgaggaagga-3Ј) and MLLint1-2R (5Ј-ctcctcttcaaagacatctg-3Ј).
Results and discussion
FLT3/ITD within exon 11 were observed in three out of 82 patients with t-MDS or t-AML. Sequence analysis showed that the in-frame duplications varied from 24 to 57 bp, and in all three cases included parts of, or the whole tyrosine-rich stretch between codons 589 and 599 (Table 1 , upper part). The three patients with FLT3/ITD all belong to the larger group of 26 patients presenting as overt t-AML showing duplication in 11.5% of the cases, and to the very small subgroup of only six cases with overt t-AML and a normal karyotype (P = 0.0043, Fishers exact test, two-sided). The normal karyotype in these three patients was confirmed by multicolor FISH.
The FLT/ITD were not related to any specific type of previous therapy. Case 64 was primarily treated with an alkylating agent. Case 105 was treated with combination chemotherapy including cisplatin and etoposide, a topoisomerase II inhibitor, whereas case R was treated with other cytostatic drugs not known as leukemogenic ( Table 2 , upper part). Patient 64 was particularly interesting. Sixty-one months after the start of dihydroxybusulphan this patient presented overt t-AML of subtype M1 with a normal karyotype. Complete remission was obtained by standard therapy with daunorubicin and cytosine arabinoside. After another 37 months relapse of t-AML was observed, now of subtype M3 with a t(15;17). The t(15;17) was confirmed by painting probes for chromosomes 15 and 17 and by RT-PCR for rearrangement between the PML and RARA genes. PCR and subsequent sequence analysis disclosed an identical FLT3/ITD in cells at primary diagnosis and in cells at relapse. This indicates that the FLT3/ITD in this case was the primary event whereas the t(15;17) was a secondary event probably induced by treatment with the topoisomerase II inhibitor, daunorubicin. As patient R with a normal karyotype had received drugs without a leukemogenic potential she probably represents a case of de novo AML.
In de novo AML FLT3/ITD have recently attracted much Leukemia attention. [13] [14] [15] [16] [17] [18] In larger series of patients these duplications have been observed in 15-23% of the patients, [13] [14] [15] [16] [17] [18] mainly in cases with a normal karyotype or a t(15;17). [16] [17] [18] This was also the case in the three patients with t-AML in the present study, and the frequency of FLT3/ITD in overt t-AML of 11.5% is not significantly different from the frequency in de novo AML. In de novo MDS, FLT3/ITD have been observed much more rarely, 14, 15 and if present they suggest transition to overt AML. 14 In de novo AML FLT3/ITD imply a poor prognosis 14, 16, 17 as observed in two out of three patients with t-AML and FLT3/ITD in the present study.
MLL/ITD were demonstrated by RT-PCR in two patients, in case 159 spanning exons 2 to 8, and in case 180 spanning exons 2 to 6. Expand PCR of genomic DNA and gel electrophoresis showed a band of approximately 2.3 kb in case 159 and a band of 1.1 kb in case 180. Subsequent sequence analysis disclosed junction points within Alu-repeats in both patients ( Table 1 , lower part) suggesting that the MLL/ITD are generated by Alu-mediated homologous recombination, similar to findings in de novo AML. 21 The 82 patients were also screened for MLL/ITD with primer set 2. With the nested primers 6.1 and 4.2R, 19 RT-PCR amplification surprisingly showed a band of 751 bp for case 159 and a band of 505 bp for case 180. Subsequent sequence analysis disclosed an identical deletion of 2517-bp from the 5Ј portion of exon 3 in both patients. Expand PCR of cDNA with primers 6.1 and 4.2R confirmed these results, indicating the same alternative splice site in exon 3 in these two cases.
The MLL/ITD were not related to any specific type of previous treatment as this differed completely in the two patients ( Table 2 , lower part). In fact case 180 with a normal karyotype confirmed by multicolor FISH most likely represents a case of de novo MDS, as methotrexate has not been demonstrated as leukemogenic. The other patient, case 159, was multitreated and presented as overt t-AML of FAB subtype M1. The karyotype was completely uncharacteristic for t-MDS and t-AML, 1-3 and the AML1 gene at chromosome band 21q22 was shown by FISH to be unrearranged.
In larger series of de novo AML MLL/ITD have been observed in 3-4% of unselected cases, most often patients with a normal karyotype. 22 In selected patients with a normal karyotype, 11% have been shown to present MLL/ITD 23 not significantly different from 8% in the present study of overt t-AML. In the rare subgroup of patients with de novo AML and trisomy 11, MLL/ITD are very common. 19, 20, 22, 23 MLL/ITD, like FLT3/ITD, are associated with a poor prognosis, 22, 23 as demonstrated also by the present study ( Table 2 ). Mutations of p53 were not observed in any of the five patients with FLT3/ITD or MLL/ITD. 5 Mutations in exons 1 to 10 of WT1 were not observed in any of our 82 patients with t-MDS or t-AML. The SSCP analysis showed diverging band patterns for exon 7 in 24 cases. Sequence analysis, however, disclosed an A to G transition at nucleotide 903 (codon 301) in these cases which is a commonly observed polymorphism. Sequence analysis in patient 166, the only case with a unique, aberrantly migrating SSCP band, showed a T to C transition in intron 6, 9 bp from exon 7.
In two previous studies of de novo AML, WT1 mutations were observed in six out of 46 patients 27 and in five out of 37 patients. 28 In two other studies, however, mutations of WT1 were not observed in a total of 26 cases of AML. 25, 26 Clinical and cytogenetic characteristics have only been provided for a few patients with de novo AML and WT1 mutations. Characteristically, these were young patients with a normal karyotype or a balanced translocation, but despite F, female; M, male; MOPP, mechlorethamine + vincristin + procarbazine + prednisone; ABVD, doxorubicin + bleomycin + vinblastin + dacarbazine; BEAM, carmustine + etoposide + cytosine arabinoside + melphalan; ASCT, autologous stem cell transplantation.
these findings they often presented an aggressive course and a short survival. Although t-MDS and t-AML are closely related to previous exposure to highly mutagenic and carcinogenic cytostatic agents, mutations of WT1 are apparently not involved in the genetic pathways of these diseases.
In conclusion, FLT3/ITD and MLL/ITD were mainly observed in the very small subgroup of patients with overt t-AML and a normal karyotype. As these characteristics are atypical and only observed in 10% of cases of t-MDS and t-AML 1,2 and because the FLT3/ITD and MLL/ITD were completely unrelated to the type of primary therapy, these patients possibly represent incidental cases of de novo AML. The experience from t-MDS and t-AML raises questions regarding the etiology of MDS and AML generally. Thus, different exogenous mutational exposures should be considered in the etiology for the subgroup of patients with de novo AML and deletions or loss of 5q and 7q, and for the subgroup of patients with de novo AML and the recurrent balanced chromosome aberrations. Based on results, also of the present study, spontaneous endogenous gene recombinations should be considered in the etiology for the major subgroup of de novo AML and for the minor subgroup of t-AML with a normal karyotype.
